1	[	[	O	(	O	16	DEP	-1
2	Clinical	Clinical	B-NP	JJ	O	3	NMOD	-1
3	significance	significance	I-NP	NN	O	16	DEP	-1
4	of	of	B-PP	IN	O	3	NMOD	-1
5	interleukin-6	interleukin-6	B-NP	NN	B-protein	4	PMOD	-1
6	(	(	O	(	O	8	DEP	-1
7	IL-6	IL-6	B-NP	NN	B-protein	8	DEP	-1
8	)	)	O	)	O	5	NMOD	-1
9	as	as	B-PP	IN	O	3	NMOD	-1
10	a	a	B-NP	DT	O	12	NMOD	-1
11	prognostic	prognostic	I-NP	JJ	O	12	NMOD	-1
12	factor	factor	I-NP	NN	O	9	PMOD	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	cancer	cancer	B-NP	NN	O	15	NMOD	-1
15	disease	disease	I-NP	NN	O	13	PMOD	-1
16	]	]	O	)	O	0	ROOT	-1

1	Interleukin-6	Interleukin-6	B-NP	NN	B-protein	5	SUB	-1
2	(	(	O	(	O	4	DEP	-1
3	IL-6	IL-6	B-NP	NN	B-protein	4	DEP	-1
4	)	)	O	)	O	1	NMOD	-1
5	is	be	B-VP	VBZ	O	0	ROOT	-1
6	proinflammatory	proinflammatory	B-NP	JJ	B-protein	7	NMOD	-1
7	cytokine	cytokine	I-NP	NN	I-protein	5	PRD	-1
8	that	that	B-NP	WDT	O	7	NMOD	-1
9	produces	produce	B-VP	VBZ	O	8	SBAR	0
10	multifunctional	multifunctional	B-NP	JJ	O	11	NMOD	-1
11	effects	effect	I-NP	NNS	O	9	OBJ	0
12	.	.	O	.	O	5	P	-1

1	It	It	B-NP	PRP	O	2	SUB	-1
2	is	be	B-VP	VBZ	O	0	ROOT	-1
3	also	also	I-VP	RB	O	2	VMOD	-1
4	involved	involve	I-VP	VBN	O	2	VC	0
5	in	in	B-PP	IN	O	4	VMOD	-1
6	the	the	B-NP	DT	O	7	NMOD	-1
7	regulation	regulation	I-NP	NN	O	5	PMOD	0
8	of	of	B-PP	IN	O	7	NMOD	-1
9	immune	immune	B-NP	JJ	O	10	NMOD	-1
10	reactions	reaction	I-NP	NNS	O	15	NMOD	-1
11	,	,	O	,	O	15	P	-1
12	hematopoiesis	hematopoiesis	B-NP	NN	O	15	NMOD	-1
13	and	and	O	CC	O	15	NMOD	-1
14	inflammatory	inflammatory	B-NP	JJ	O	15	NMOD	-1
15	state	state	I-NP	NN	O	8	PMOD	-1
16	.	.	O	.	O	2	P	-1

1	Interleukin-6	Interleukin-6	B-NP	NN	B-protein	2	SUB	-1
2	has	have	B-VP	VBZ	O	0	ROOT	-1
3	been	be	I-VP	VBN	O	2	VC	-1
4	shown	show	I-VP	VBN	O	3	VC	-1
5	to	to	I-VP	TO	O	6	VMOD	-1
6	be	be	I-VP	VB	O	4	VMOD	-1
7	associated	associate	I-VP	VBN	O	6	VC	16	associated
8	with	with	B-PP	IN	O	7	VMOD	-1
9	tumor	tumor	B-NP	NN	O	10	NMOD	-1
10	progression	progression	I-NP	NN	O	8	PMOD	2	progression
11	including	include	B-PP	VBG	O	10	NMOD	-1
12	inhibition	inhibition	B-NP	NN	O	11	PMOD	18	inhibition
13	of	of	B-PP	IN	O	12	NMOD	-1
14	cancer	cancer	B-NP	NN	B-cell_type	15	NMOD	-1
15	cells	cell	I-NP	NNS	I-cell_type	18	NMOD	-1
16	apoptosis	apoptosis	B-NP	NN	O	18	NMOD	5	apoptosis
17	and	and	I-NP	CC	O	18	NMOD	-1
18	stimulation	stimulation	I-NP	NN	O	13	PMOD	17	stimulation
19	of	of	B-PP	IN	O	18	NMOD	-1
20	angiogenesis	angiogenesis	B-NP	NN	O	19	PMOD	3	angiogenesis
21	.	.	O	.	O	2	P	-1

1	Anti-IL-6	Anti-IL-6	B-NP	NN	B-protein	2	NMOD	-1
2	therapy	therapy	I-NP	NN	O	3	SUB	19	therapy
3	is	be	B-VP	VBZ	O	0	ROOT	-1
4	a	a	B-NP	DT	O	6	NMOD	-1
5	new	new	I-NP	JJ	O	6	NMOD	-1
6	strategy	strategy	I-NP	NN	O	3	PRD	-1
7	in	in	B-PP	IN	O	6	NMOD	-1
8	the	the	B-NP	DT	O	11	NMOD	-1
9	inflammatory	inflammatory	I-NP	JJ	O	11	NMOD	-1
10	autoimmune	autoimmune	I-NP	JJ	O	11	NMOD	-1
11	diseases	disease	I-NP	NNS	O	13	NMOD	-1
12	and	and	O	CC	O	13	NMOD	-1
13	cancer	cancer	B-NP	NN	O	7	PMOD	-1
14	.	.	O	.	O	3	P	-1

1	Clinical	Clinical	B-NP	JJ	O	2	NMOD	-1
2	studies	study	I-NP	NNS	O	3	SUB	-1
3	have	have	B-VP	VBP	O	0	ROOT	-1
4	shown	show	I-VP	VBN	O	3	VC	-1
5	elevated	elevated	B-NP	JJ	O	8	NMOD	17	elevated
6	serum	serum	I-NP	NN	O	8	NMOD	-1
7	IL-6	IL-6	I-NP	NN	B-protein	8	NMOD	-1
8	concentrations	concentration	I-NP	NNS	O	30	NMOD	-1
9	in	in	B-PP	IN	O	8	NMOD	-1
10	patients	patient	B-NP	NNS	O	9	PMOD	-1
11	with	with	B-PP	IN	O	10	NMOD	-1
12	endometrial	endometrial	B-NP	JJ	O	13	NMOD	-1
13	cancer	cancer	I-NP	NN	O	11	PMOD	-1
14	,	,	O	,	O	30	P	-1
15	non-small	non-small	B-NP	JJ	O	18	NMOD	-1
16	cell	cell	I-NP	NN	O	18	NMOD	-1
17	lung	lung	I-NP	NN	O	18	NMOD	-1
18	carcinoma	carcinoma	I-NP	NN	O	30	NMOD	-1
19	,	,	O	,	O	30	P	-1
20	colorectal	colorectal	B-NP	JJ	O	21	NMOD	-1
21	cancer	cancer	I-NP	NN	O	30	NMOD	-1
22	,	,	O	,	O	30	P	-1
23	renal	renal	B-NP	JJ	O	25	NMOD	-1
24	cell	cell	I-NP	NN	O	25	NMOD	-1
25	carcinoma	carcinoma	I-NP	NN	O	30	NMOD	-1
26	,	,	O	,	O	30	P	-1
27	breast	breast	B-NP	NN	O	30	NMOD	-1
28	and	and	O	CC	O	30	NMOD	-1
29	ovarian	ovarian	B-NP	JJ	O	30	NMOD	-1
30	cancer	cancer	I-NP	NN	O	4	OBJ	-1
31	.	.	O	.	O	3	P	-1

1	Serum	Serum	B-NP	NN	O	3	NMOD	-1
2	IL-6	IL-6	I-NP	NN	B-protein	3	NMOD	-1
3	levels	level	I-NP	NNS	O	4	SUB	-1
4	correlate	correlate	B-VP	VBP	O	0	ROOT	-1
5	with	with	B-PP	IN	O	4	VMOD	-1
6	tumor	tumor	B-NP	NN	O	7	NMOD	-1
7	stage	stage	I-NP	NN	O	5	PMOD	-1
8	,	,	O	,	O	10	P	-1
9	and	and	O	CC	O	10	NMOD	-1
10	survival	survival	B-NP	NN	O	4	OBJ	5	survival
11	of	of	B-PP	IN	O	10	NMOD	-1
12	patients	patient	B-NP	NNS	O	11	PMOD	-1
13	.	.	O	.	O	4	P	-1

1	In	In	B-PP	IN	O	5	VMOD	-1
2	this	this	B-NP	DT	O	3	NMOD	-1
3	article	article	I-NP	NN	O	1	PMOD	-1
4	we	we	B-NP	PRP	O	5	SUB	-1
5	have	have	B-VP	VBP	O	0	ROOT	-1
6	focused	focus	I-VP	VBN	O	5	VC	-1
7	on	on	B-PP	IN	O	6	VMOD	-1
8	a	a	B-NP	DT	O	9	NMOD	-1
9	role	role	I-NP	NN	O	7	PMOD	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	IL-6	IL-6	B-NP	NN	B-protein	10	PMOD	-1
12	as	as	B-PP	IN	O	9	NMOD	-1
13	a	a	B-NP	DT	O	15	NMOD	-1
14	prognostic	prognostic	I-NP	JJ	O	15	NMOD	-1
15	factor	factor	I-NP	NN	O	12	PMOD	-1
16	in	in	B-PP	IN	O	15	NMOD	-1
17	several	several	B-NP	JJ	O	18	NMOD	-1
18	malignancies	malignancy	I-NP	NNS	O	16	PMOD	-1
19	such	such	B-PP	JJ	O	20	PMOD	-1
20	as	as	I-PP	IN	O	18	NMOD	-1
21	colorectal	colorectal	B-NP	JJ	O	22	NMOD	-1
22	cancer	cancer	I-NP	NN	O	31	NMOD	-1
23	,	,	O	,	O	31	P	-1
24	breast	breast	B-NP	NN	O	25	NMOD	-1
25	cancer	cancer	I-NP	NN	O	31	NMOD	-1
26	,	,	O	,	O	31	P	-1
27	gastric	gastric	B-NP	JJ	O	28	NMOD	-1
28	cancer	cancer	I-NP	NN	O	31	NMOD	-1
29	and	and	O	CC	O	31	NMOD	-1
30	pancreatic	pancreatic	B-NP	JJ	O	31	NMOD	-1
31	cancer	cancer	I-NP	NN	O	20	PMOD	-1
